Category: PIPELINE

Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias

Gyala Therapeutics raises €3 million to advance CAR-T therapy GYA01 into clinical development